- Home
- CHPT vs IMMP Comparison
CHPT vs IMMP Comparison
Compare CHPT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- IMMP
- Stock Information
- Founded
- CHPT 2007
- IMMP 1987
- Country
- CHPT United States
- IMMP Australia
- Employees
- CHPT N/A
- IMMP N/A
- Industry
- CHPT Industrial Specialties
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- IMMP Health Care
- Exchange
- CHPT Nasdaq
- IMMP Nasdaq
- Market Cap
- CHPT 256.9M
- IMMP 256.1M
- IPO Year
- CHPT N/A
- IMMP N/A
- Fundamental
- Price
- CHPT $8.70
- IMMP $1.88
- Analyst Decision
- CHPT Hold
- IMMP Buy
- Analyst Count
- CHPT 11
- IMMP 1
- Target Price
- CHPT $18.40
- IMMP $7.00
- AVG Volume (30 Days)
- CHPT 364.2K
- IMMP 142.4K
- Earning Date
- CHPT 12-04-2025
- IMMP 02-22-2026
- Dividend Yield
- CHPT N/A
- IMMP N/A
- EPS Growth
- CHPT N/A
- IMMP N/A
- EPS
- CHPT N/A
- IMMP N/A
- Revenue
- CHPT $397,731,000.00
- IMMP $3,306,742.00
- Revenue This Year
- CHPT N/A
- IMMP N/A
- Revenue Next Year
- CHPT $12.67
- IMMP N/A
- P/E Ratio
- CHPT N/A
- IMMP N/A
- Revenue Growth
- CHPT N/A
- IMMP 31.28
- 52 Week Low
- CHPT $8.55
- IMMP $1.32
- 52 Week High
- CHPT $30.00
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- CHPT 29.82
- IMMP 51.34
- Support Level
- CHPT $9.25
- IMMP $1.78
- Resistance Level
- CHPT $9.97
- IMMP $2.08
- Average True Range (ATR)
- CHPT 0.49
- IMMP 0.08
- MACD
- CHPT -0.17
- IMMP -0.01
- Stochastic Oscillator
- CHPT 0.00
- IMMP 51.16
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.